title: Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
abstract: BACKGROUND
  The DNA repair protein O6-alkylguanine-DNA alkyl transferase (AT) mediates resistance to chloroethylnitrosoureas. Agents depleting AT such as DTIC and its new analogue temozolomide (TMZ) can reverse resistance to chloroethylnitrosoureas. We report the results of a dose finding study of TMZ in association with fotemustine.
  
  
  METHODS
  Twenty-four patients with metastatic melanoma or recurrent glioma were treated with escalating dose of oral or intravenous TMZ ranging from 300 to 700 mg/m2, divided over two days. Fotemustine 100 mg/m2 was given intravenously on day 2, 4 hours after TMZ. AT depletion was measured in peripheral blood mononuclear cells (PBMCs) and in selected cases in melanoma metastases and was compared to TMZ pharmacokinetics.
  
  
  RESULTS
  The maximum tolerated dose (MTD) of TMZ was 400 mg/m2 (200 mg/m2/d) when associated with fotemustine the 2nd day with myelosuppression as dose limiting toxicity. The decrease of AT level in PBMCs was progressive and reached 34% of pretreatment values on day 2. There was however wide interindividual variability. AT reduction was neither dose nor route dependent and did not appear to be related to TMZ systemic exposure (AUC). In the same patients, AT depletion in tumour did not correlate with the decrease of AT observed in PBMCs.
  
  
  CONCLUSIONS
  PBMCs may not be used as a surrogate of tumour for AT depletion. Further study should concentrate on the pharmacokinetic pharmacodynamic relationship in tumour to provide the basis for individually tailored therapy.
authors.affiliation: Centre Pluridisciplinaire d'Oncologie, Lausanne, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Gander
authors.forename: S
authors.initials: S
authors.lastname: Leyvraz
authors.forename: L
authors.initials: L
authors.lastname: Decosterd
authors.forename: M
authors.initials: M
authors.lastname: Bonfanti
authors.forename: C
authors.initials: C
authors.lastname: Marzolini
authors.forename: F
authors.initials: F
authors.lastname: Shen
authors.forename: D
authors.initials: D
authors.lastname: Liénard
authors.forename: L
authors.initials: L
authors.lastname: Perey
authors.forename: G
authors.initials: G
authors.lastname: Colella
authors.forename: J
authors.initials: J
authors.lastname: Biollaz
authors.forename: F
authors.initials: F
authors.lastname: Lejeune
authors.forename: D
authors.initials: D
authors.lastname: Yarosh
authors.forename: M
authors.initials: M
authors.lastname: Belanich
authors.forename: M
authors.initials: M
authors.lastname: D'Incalci
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D001932:Brain Neoplasms / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D005910:Glioma / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D008214:Lymphocytes / Q000201:enzymology*; D008297:Male; D008545:Melanoma / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000097:blood*; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077204:Temozolomide
chemical_list: D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; C054368:fotemustine; D000077204:Temozolomide